Bioneer is in the forefront of neurodegenerative disease modelling, and have many years’ experience with induced pluripotent stem cells (iPSCs) as well as reprogramming and gene editing technologies. In the beginning of 2019, we published three papers together with our R&D partners in the peer reviewed journal of Stem Cell Research covering the work on different in vitro disease models for the neurodegenerative disease Alzheimer’s disease (AD).

The papers summarize research in human disease modelling being carried out in connection to several national and European projects. In the most recent publication, the generation of an AD model based on iPSC-cells and gene editing of the PSEN1 gene is described, a work that has been done in the framework of the nationally funded BrainStem project.  In the second publication, the work on generating a complete iPSC-based APOE model is described. Bioneer has mainly run this development together with Janssen, a leading pharmaceutical company, through the comprehensive IMI project called EBiSC. In the third and last publication, Bioneer has within the national project called NeuroStem contributed to another AD model focusing on the APP gene.

For more information about disease modelling at Bioneer, please contact R&D Manager Bjørn Holst via email or call +45 45 160 444.

The publications are available at ScienceDirect:

Fredriksen et al. (Feb 2019). Generation of two isogenic iPSC lines with either a heterozygous or a homozygous E280A mutation in the PSEN1 gene. LINK

Schmid et al. (Jan 2019) Generation of a set of isogenic, gene-edited iPSC lines homozygous for all main APOE variants and an APOE knock-out line. LINK

Fredriksen et al. (Jan 2019) Generation of two iPSC lines with either a heterozygous V717I or a heterozygous KM670/671NL mutation in the APP gene. LINK

EBiSC is a not-for-profit iPSC depository called European Bank for induced pluripotent Stem Cells, supported jointly between 2014-2017 by the Innovative Medicines Initiative (IMI) and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
BrainStem is the Stem Cell Center of Excellence in Neurology consisting of 9 partners and funded by the Innovation Fund Denmark by 3+ MEUR between 2015 and 2020. The focus is on research in neurodegenerative diseases.
NeuroStem is an Indo-Danish strategic research cooperation within Health Science Biotechnology funded by a 5 MDKK grant from the Innovation Fund Denmark (2015-2018). The aim is to establish iPSC-based patient-specific in vitro screening platforms for investigation of RNA-mediated neurodegeneration.